The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100 and IV Ketamine.
David Meltzer of “Office Hours” interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine.
Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H., Chairman and Chief Scientist, NRx Pharmaceuticals, discussing the anti-depressant effect of Ketamine.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
See our Chief Scientist, Dr. Jonathan C. Javitt, provide a comprehensive description on why we are committed to solve for a very high unmet need in bipolar depression with suicidality.
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.
